Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity

Journal of Clinical Pharmacology

Volumn 42, Issue 9, 2002, Pages 1020-1026

  Ishii, Yoko ^a   Nakamura, Koichi ^a   Matsuki, Shunji ^a   Uemura, Naoto ^a   Muraguchi, Ryoko ^a   Nakagawa, Mikiko ^a   Nakano, Shigeyuki ^a   Nakatsuka, Kazuo ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL TEAR; CARTEOLOL; CYTOCHROME P450 2D6; MYTEAR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; GEOMETRY; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR PRESSURE; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; DRUG EFFECT; INTRANASAL DRUG ADMINISTRATION; JAPAN; METABOLISM; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AREA UNDER CURVE; CARTEOLOL; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; JAPAN; MALE; OPHTHALMIC SOLUTIONS;

EID: 0036708027     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002042009009     Document Type: Article

References (43)

1. Stimulation of aqueous humor flow by ANF, turbutaline and VIP: Effects of timolol
2. Ion channel activity of ciliary process epithelium vesicles reconstituted into planar bilayers
3. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985
4. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents
5. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: Potential for oral-ophthalmic drug interaction
6. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients
7. Beta-blocking effects of timolol at low plasma concentrations
8. Improving the therapeutic index of topically applied ocular drugs
9. Effect of nasolacrimal occlusion on timolol concentrations in the aqueous humor of the human eye
10. The contralateral reduction of intraocular pressure by timolol
11. Beta blocker induced ocular hypotension via central nervous system
12. Sublingual timolol: An alternative to topical medication in glaucoma?
13. Ocular hypotensive effect of sublingual administration of timolol
14. Conjunctival vs. sublingual administration of carteolol 2% eye drops: Ocular hypotensive effects and some systemic parameter changes
15. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure: Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group
16. Ocular effects of carteolol and pharmacokinetics in volunteers
17. Metabolism of carteolol by cDNA-expressed human cytochrome P450
18. Polymorphichydroxylation of debrisoquine in man
19. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
20. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation
21. Pharmacokinetic and pharmacodynamic interactions among haloperidol, carteolol hydrochloride and biperiden hydrochloride
22. Interaction between timolol eyedrops and oral nicardipine or oral diltiazem in healthy Japanese subjects
23. Absorption of ocular timolol
24. Basis for dosing time-dependent changes in the ocular and systemic absorption of topically applied timolol
25. Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: Implications in the design of strategies to maximize the ratio of ocular to systemic absorption
26. Intranasal drug delivery by spray and drops
27. Intranasal drug delivery: Potential advantages and limitations from a clinical pharmacokinetic perspective
28. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity
29. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: A comparison with corneal penetration
30. Systemic absorption of ocular timolol in poor and extensive metabolizers of debrisoquine
31. Systemic absorption of topically applied ocular drugs in humans
32. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent
33. Determination of low plasma timolol concentrations following topical application of timolol eye drops in humans by high-performance liquid chromatography with electrochemical detection
34. The analysis of plasma kinetics and beta-receptor binding and -blocking activity of timolol following its small intravenous dose
35. Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes
36. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middleaged men
37. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
38. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects
39. Drug interaction between cimetidine and timolol ophthalmic solution: Effect on heart rate and intraocular pressure in healthy Japanese volunteers
40. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity
41. Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers
42. Concentration-effect and time-effect relationships of carteolol
43. Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists